Insider · CIK 0001727550

FONTEYNE PAUL R.

Reports to the SEC for 7 companies · CAMBRIDGE, MA

sec.gov

Transactions

Companies

Filings

CIK

0001727550

Forms 4 and 5

Insider transactions

50 trades

Date	Company	Role	Code	Shares	Price	Value	Shares after
2026-08-03	APMDApnimed, Inc. · Stock Option (Right to Buy)A Award	Director	AAward	+44.5K sh	—	—	44,477
2026-08-03	APMDApnimed, Inc. · Stock Option (Right to Buy)A Award	Director	AAward	+51.9K sh	—	—	51,890
2026-08-03	APMDApnimed, Inc. · Stock Option (Right to Buy)D Disposition to Issuer	Director	DDisposition to Issuer	−51.9K sh	—	—	0
2026-08-03	APMDApnimed, Inc. · Stock Option (Right to Buy)D Disposition to Issuer	Director	DDisposition to Issuer	−44.5K sh	—	—	0
2026-08-03	APMDApnimed, Inc. · Stock Option (Right to Buy)D Disposition to Issuer	Director	DDisposition to Issuer	−44.5K sh	—	—	0
2026-08-03	APMDApnimed, Inc. · Stock Option (Right to Buy)A Award	Director	AAward	+44.5K sh	—	—	44,477
2026-07-30	APMDApnimed, Inc. · Stock Option (Right to Buy)A Award	Director	AAward	+44.5K sh	—	—	44,477
2026-06-04	AMLXAmylyx Pharmaceuticals, Inc. · Stock Option (right to buy)A Award	Director	AAward	+24.4K sh	—	—	24,372
2026-05-14	APLSApellis Pharmaceuticals, Inc.D Disposition to Issuer	Director	DDisposition to Issuer	−3,877 sh	—	—	0
2026-05-14	APLSApellis Pharmaceuticals, Inc.D Disposition to Issuer	Director	DDisposition to Issuer	−3,544 sh	—	—	0
2026-05-14	APLSApellis Pharmaceuticals, Inc.D Disposition to Issuer	Director	DDisposition to Issuer	−7,961 sh	—	—	0
2026-05-14	APLSApellis Pharmaceuticals, Inc.D Disposition to Issuer	Director	DDisposition to Issuer	−5,744 sh	—	—	0
2026-05-14	APLSApellis Pharmaceuticals, Inc.U Disposition from Tender	Director	UDisposition from Tender	−30.7K sh	—	—	0
2026-05-14	APLSApellis Pharmaceuticals, Inc.D Disposition to Issuer	Director	DDisposition to Issuer	−3,062 sh	—	—	0
2026-05-14	APLSApellis Pharmaceuticals, Inc. · Stock Option (right to buy)D Disposition to Issuer	Director	DDisposition to Issuer	−5,748 sh	—	—	0
2026-05-14	APLSApellis Pharmaceuticals, Inc. · Stock Option (right to buy)D Disposition to Issuer	Director	DDisposition to Issuer	−27.6K sh	—	—	0
2026-05-14	APLSApellis Pharmaceuticals, Inc. · Stock Option (right to buy)D Disposition to Issuer	Director	DDisposition to Issuer	−7,441 sh	—	—	0
2026-05-14	APLSApellis Pharmaceuticals, Inc. · Stock Option (right to buy)D Disposition to Issuer	Director	DDisposition to Issuer	−8,554 sh	—	—	0
2026-05-14	APLSApellis Pharmaceuticals, Inc. · Stock Option (right to buy)D Disposition to Issuer	Director	DDisposition to Issuer	−11.2K sh	—	—	0
2026-05-14	APLSApellis Pharmaceuticals, Inc. · Stock Option (right to buy)D Disposition to Issuer	Director	DDisposition to Issuer	−37.5K sh	—	—	0
2026-05-14	APLSApellis Pharmaceuticals, Inc. · Stock Option (right to buy)D Disposition to Issuer	Director	DDisposition to Issuer	−14.7K sh	—	—	0
2026-01-01	APLSApellis Pharmaceuticals, Inc. · Stock Option (Right to Buy)A Award	Director	AAward	+14.7K sh	—	—	14,684
2026-01-01	APLSApellis Pharmaceuticals, Inc.A Award	Director	AAward	+7,961 sh	—	—	30,666
2025-06-05	AMLXAmylyx Pharmaceuticals, Inc. · Stock Option (right to buy)A Award	Director	AAward	+25K sh	—	—	25,000
2025-01-01	APLSApellis Pharmaceuticals, Inc.A Award	Director	AAward	+6,267 sh	—	—	22,705
2025-01-01	APLSApellis Pharmaceuticals, Inc. · Stock Option (Right to Buy)A Award	Director	AAward	+11.2K sh	—	—	11,199
2024-06-06	AMLXAmylyx Pharmaceuticals, Inc. · Stock Option (right to buy)A Award	Director	AAward	+25K sh	—	—	25,000
2024-01-01	APLSApellis Pharmaceuticals, Inc.A Award	Director	AAward	+3,341 sh	—	—	16,438
2024-01-01	APLSApellis Pharmaceuticals, Inc. · Stock Option (Right to Buy)A Award	Director	AAward	+5,748 sh	$59.86	+$344K	5,748
2023-06-08	AMLXAmylyx Pharmaceuticals, Inc. · Stock Option (right to buy)A Award	Director	AAward	+17K sh	—	—	16,985
2023-01-01	APLSApellis Pharmaceuticals, Inc.A Award	Director	AAward	+3,867 sh	—	—	13,097
2023-01-01	APLSApellis Pharmaceuticals, Inc. · Stock Option (Right to Buy)A Award	Director	AAward	+7,441 sh	—	—	7,441
2022-10-13	COVETRUS, INC.Restricted Stock UnitsD Disposition to Issuer	Director	DDisposition to Issuer	−14.6K sh	—	—	0
2022-10-13	COVETRUS, INC.D Disposition to Issuer	Director	DDisposition to Issuer	−13.3K sh	—	—	0
2022-07-01	COVETRUS, INC.M Exercise/Conversion	Director	MExercise/Conversion	+8,275 sh	—	—	13,275
2022-07-01	COVETRUS, INC.Restricted Stock UnitsM Exercise/Conversion	Director	MExercise/Conversion	−8,275 sh	—	—	0
2022-06-09	AMLXAmylyx Pharmaceuticals, Inc. · Stock Option (Right to Buy)A Award	Director	AAward	+19K sh	—	—	19,000
2022-05-11	COVETRUS, INC.Restricted Stock UnitsA Award	Director	AAward	+14.6K sh	—	—	14,638
2022-05-06	GELESIS HOLDINGS, INC.A Award	Director	AAward	+53.8K sh	—	—	53,832
2022-01-06	AMLXAmylyx Pharmaceuticals, Inc. · Stock Option (Right to Buy)A Award	Director	AAward	+8,400 sh	—	—	8,400
2022-01-06	AMLXAmylyx Pharmaceuticals, Inc.P Purchase	Director	PPurchase	+3,947 sh	$19.00	+$75K	3,947
2022-01-01	APLSApellis Pharmaceuticals, Inc. · Stock Option (Right to Buy)A Award	Director	AAward	+8,554 sh	—	—	8,554
2022-01-01	APLSApellis Pharmaceuticals, Inc.A Award	Director	AAward	+4,230 sh	—	—	9,230
2021-08-10	COVETRUS, INC.P Purchase	Director	PPurchase	+5,000 sh	$23.24	+$116K	5,000
2021-07-01	COVETRUS, INC.Restricted Stock UnitsA Award	Director	AAward	+8,275 sh	—	—	8,275
2021-01-01	APLSApellis Pharmaceuticals, Inc. · Stock Option (Right to Buy)A Award	Director	AAward	+27.6K sh	—	—	27,600
2020-11-16	AMAG PHARMACEUTICALS, INC.Stock Option (Right to Buy)D Disposition to Issuer	Director	DDisposition to Issuer	−6,000 sh	—	—	0
2020-11-16	AMAG PHARMACEUTICALS, INC.Stock Option (Right to Buy)D Disposition to Issuer	Director	DDisposition to Issuer	−21.3K sh	—	—	0
2020-11-16	AMAG PHARMACEUTICALS, INC.Stock Option (Right to Buy)D Disposition to Issuer	Director	DDisposition to Issuer	−9,452 sh	—	—	0
2020-11-16	AMAG PHARMACEUTICALS, INC.D Disposition to Issuer	Director	DDisposition to Issuer	−14.7K sh	—	—	0

Recent filings

Accepted (ET)
Aug 34
FONTEYNE PAUL R.0001193125-26-330508
SEC(opens sec.gov)
Jun 84
FONTEYNE PAUL R.0001193125-26-261637
SEC(opens sec.gov)
May 144
FONTEYNE PAUL R.0001193125-26-224618
SEC(opens sec.gov)

Companies

Address

APNIMED, INC. 39 JOHN F. KENNEDY STREET, 4TH FLOOR

CAMBRIDGE, MA, 02138